Advanced Filters
noise

Spinal Cord Malignancy Clinical Trials

A listing of Spinal Cord Malignancy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 36 clinical trials
P Peter Kirrander, MD PhD

Lymphedema After Urologic Surgery

Lymphedema of the extremities is common after lymph node surgery in treating several forms of cancer, e.g., breast cancer. However, very little is known of the occurrence of lymphedema of the lower extremities after urologic surgery with lymph node dissection. This project aims to describe the frequency and grade of …

18 years of age All Phase N/A
M Mette Pernille Myklebust, PhD

MicroRNA as Markers in Testicular Cancer

The main objective of this study is establish the performance of miR371 in management of testicular cancer

18 - 70 years of age Male Phase N/A

THERApy De-escalation for TESTicular Cancer

THERATEST is looking to collect data from 30 patients actively receiving de-escalation treatments or other standard of care treatments in two UK hospitals. THERATEST is a feasibility study to determine whether patients are willing to be recruited, the impact of de-escalation treatments on patients' cancers and quality of life, whether …

16 years of age Male Phase N/A
B Barbara JT Nordhjem, PhD

Investigating Cognitive Impairment in Young Patients With Cancer Prospectively

The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer. The tests include 1) cognitive skills such as memory and attention; 2) the brain's electrical activity; 3) and biological markers related to brain function. The aim of the study is …

7 - 29 years of age All Phase N/A
J J. Nuver, MD, PhD

Early Ageing During Therapy in AYA Cancer Patients

Longitudinal cohort study; measurements before start of systemic therapy and one year later.

18 - 39 years of age All Phase N/A

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US

18 - 130 years of age All Phase N/A

Simplify language using AI